ERBB2 and gastric cancer: Overall, HER2-RQDs nanoprobes represent a promising platform for in-situ gastric cancer-targeted imaging and selective therapy, with potential for further clinical translation upon addressing the aforementioned limitations, Figure 13 [36,215].